Scientific Publication

0

“Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update”

Piqué N, Miñana-Galbis D, Machlab S. Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update. Ann Pediatr Child Health 2020; 8(6): 1194.

We are proud to announce the publication “Advantages of Gel Oral Rehydration Solutions (ORS) for the Management of Acute Diarrhea: An Update”. This article elaborates on how a friendlier use of ORS is possible by improving palatability and texture, as well as limiting the volume per dosing. As a result, treatment compliance and, subsequently, therapeutic success, are more likely than with standard ORS preparations.

Read more

We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children"

Santos J. et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.Expert Rev Gastroenterol Hepatol: 2020 Oct 19;1-7. doi: 10.1080/17474124.2021.1833715.

We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.”. While Oral Rehydration (ORS) is the main treatment of acute diarrhea in children, the addition of specific antidiarrheals may speed up the reduction of symptoms. In this clinical trial, children receiving xyloglucan/gelose (vegetal ingredients of Xilaplus AF) on top of the ORS, had significantly fewer diarrheic episodes than those who received ORS alone. The improvement of symptoms in the group on Xyloglucan/gelose was evident from 6 hours after the first dose.

Read more

A new publication confirms the role of xyloglucan as a mucosa protector in the management of urinary tract infections

Esposito E et al. Effect of xyloglucan against Escherichia coli extraintestinal urinary tract infection: an in vivo study. Microb Physiol. Published online: Oct 16, 2020. DOI: 10.1159/000510874

Urinary tract infections account for the third most common type of infectious pathology after respiratory and gastrointestinal processes. The agent responsible for such urinary tract infections is in most cases the bacterium Escherichia coli that migrates from the intestine and invades the urinary tract. In a recent publication in Microbial Physiology, Dr Emanuela Esposito, of the University of Messina, under the direction of Professor Salvatore Cuzzocrea, has seen in a study conducted in rats infected with E coli as their intestinal and urinary bacterial load is significantly reduced when they are previously treated with xyloglucan alone or with xyloglucan combined with gelose. Similarly, histological lesions in the intestinal and urinary wall resulting from infection are reduced. It is thus confirmed that these polymeric substances create a physical barrier that reduces intestinal reservoirs of pathogenic bacteria supporting their beneficial role in the treatment and prevention of urinary tract infections. The marketed products containing these substances in their composition can thus see their totally innovative mode of action fully explained.

Read more

Let's meet in..